The p53 tumor suppressor in the control of metabolism and ferroptosis

Frontiers in Endocrinology

Volumn 9, Issue APR, 2018, Pages

  Gnanapradeepan, Keerthana ^a,b   Basu, Subhasree ^a   Barnoud, Thibaut ^a   Budina Kolomets, Anna ^a   Kung, Che Pei ^c   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ferroptosis; Metabolism; P53; Tumor suppressor

Indexed keywords

LIPID PEROXIDE; PROTEIN P53;

CANCER INHIBITION; CELL DEATH; FERROPTOSIS; GENETIC VARIABILITY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; LIPOGENESIS; LIPOLYSIS; METABOLISM; NON-TRANSFORMED CELL; OXIDATIVE PHOSPHORYLATION; PROTEIN POLYMORPHISM; REVIEW; TUMOR CELL;

EID: 85045273071     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2018.00124     Document Type: Review

References (57)

1. Dolgin E. The most popular genes in the human genome. Nature (2017) 551(7681):427-31. doi:10.1038/d41586-017-07291-9
2. Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol (2017) 51:65-72. doi:10.1016/j.ceb.2017.11.005
3. Humpton TJ, Vousden KH. Regulation of cellular metabolism and hypoxia by p53. Cold Spring Harb Perspect Med (2016) 6(7):211-30. doi:10.1101/cshperspect.a026146
4. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 149(5):1060-72. doi:10.1016/j.cell.2012.03.042
5. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature (2015) 520(7545):57-62. doi:10.1038/nature14344
6. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell (2011) 145(4):571-83. doi:10.1016/j.cell.2011.03.035
7. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science (2006) 312(5780):1650-3. doi:10.1126/science.1126863
8. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A (2010) 107(16):7455-60. doi:10.1073/pnas.1001006107
9. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res (2004) 64(7):2627-33. doi:10.1158/0008-5472.CAN-03-0846
10. Zhang C, Liu J, Wu R, Liang Y, Lin M, Liu J, et al. Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget (2014) 5(14):5535-46. doi:10.18632/oncotarget.2137
11. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 126(1):107-20. doi:10.1016/j.cell.2006.05.036
12. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol (2011) 13(3):310-6. doi:10.1038/ncb2172
13. Kung CP, Murphy ME. The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol (2016) 231(2):R61-75. doi:10.1530/JOE-16-0324
14. Eriksson M, Ambroise G, Ouchida AT, Lima Queiroz A, Smith D, Gimenez-Cassina A, et al. Effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol Cell Biol (2017) 37(24):1-17. doi:10.1128/MCB.00328-17
15. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun (2013) 4:2935. doi:10.1038/ncomms3935
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013
17. Lee M, Yoon JH. Metabolic interplay between glycolysis and mitochondrial oxidation: the reverse Warburg effect and its therapeutic implication. World J Biol Chem (2015) 6(3):148-61. doi:10.4331/wjbc.v6.i3.148
18. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet (2003) 33(3):357-65. doi:10.1038/ng1093
19. Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res (2015) 13(2):250-62. doi:10.1158/1541-7786.MCR-14-0385
20. Azzam GA, Frank AK, Hollstein M, Murphy ME. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle (2011) 10(9):1352-5. doi:10.4161/cc.10.9.15344
21. Bitti ML, Saccucci P, Capasso F, Piccinini S, Angelini F, Rapini N, et al. Genotypes of p53 codon 72 correlate with age at onset of type 1 diabetes in a sex-specific manner. J Pediatr Endocrinol Metab (2011) 24(7-8):437-9. doi:10.1515/jpem.2011.058
22. Bonfigli AR, Sirolla C, Testa R, Cucchi M, Spazzafumo L, Salvioli S, et al. The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study. Acta Diabetol (2013) 50(3):429-36. doi:10.1007/s00592-012-0450-x
23. Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, et al. The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction. Cell Rep (2016) 14(10):2413-25. doi:10.1016/j.celrep.2016.02.037
24. Kung CP, Liu Q, Murphy ME. The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation. Cancer Biol Ther (2017) 18(7):484-91. doi:10.1080/15384047.2017.1323595
25. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic regulation by p53 family members. Cell Metab (2013) 18(5):617-33. doi:10.1016/j.cmet.2013.06.019
26. Sanchez-Macedo N, Feng J, Faubert B, Chang N, Elia A, Rushing EJ, et al. Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ (2013) 20(4):659-68. doi:10.1038/cdd.2012.168
27. Assaily W, Rubinger DA, Wheaton K, Lin Y, Ma W, Xuan W, et al. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol Cell (2011) 44(3):491-501. doi:10.1016/j.molcel.2011.08.038
28. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab (2006) 4(3):199-210. doi:10.1016/j.cmet.2006.08.005
29. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2(101):ra82. doi:10.1126/scisignal.2000446
30. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 64(6):2212-21. doi:10.1158/0008-5472.CAN-2148-2
31. Parrales A, Iwakuma T. p53 as a regulator of lipid metabolism in cancer. Int J Mol Sci (2016) 17(12):1-17. doi:10.3390/ijms17122074
32. Yahagi N, Shimano H, Matsuzaka T, Najima Y, Sekiya M, Nakagawa Y, et al. p53 activation in adipocytes of obese mice. J Biol Chem (2003) 278(28):25395-400. doi:10.1074/jbc.M302364200
33. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell (2014) 54(6):960-74. doi:10.1016/j.molcel.2014.04.024
34. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 148(1-2):244-58. doi:10.1016/j.cell.2011.12.017
35. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A (2010) 107(34):15051-6. doi:10.1073/pnas.0910258107
36. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW. Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol (1985) (2002) 92(6):2475-82. doi:10.1152/japplphysiol.00071.2002
37. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab (2011) 13(4):376-88. doi:10.1016/j.cmet.2011.03.009
38. Ashur-Fabian O, Har-Zahav A, Shaish A, Wiener Amram H, Margalit O, Weizer-Stern O, et al. apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. Cell Cycle (2010) 9(18):3761-70. doi:10.4161/cc.9.18.12993
39. Goldstein I, Ezra O, Rivlin N, Molchadsky A, Madar S, Goldfinger N, et al. p53, a novel regulator of lipid metabolism pathways. J Hepatol (2012) 56(3):656-62. doi:10.1016/j.jhep.2011.08.022
40. Goldstein I, Rotter V. Regulation of lipid metabolism by p53-fighting two villains with one sword. Trends Endocrinol Metab (2012) 23(11):567-75. doi:10.1016/j.tem.2012.06.007
41. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell (2014) 156(1-2):317-31. doi:10.1016/j.cell.2013.12.010
42. Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A (2016) 113(34):E4966-75. doi:10.1073/pnas.1603244113
43. Magtanong L, Ko PJ, Dixon SJ. Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ (2016) 23(7):1099-109. doi:10.1038/cdd.2016.25
44. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell (2017) 171(2):273-85. doi:10.1016/j.cell.2017.09.021
45. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 149(6):1269-83. doi:10.1016/j.cell.2012.04.026
46. Wang SJ, Li D, Ou Y, Jiang L, Chen Y, Zhao Y, et al. Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep (2016) 17(2):366-73. doi:10.1016/j.celrep.2016.09.022
47. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell (2015) 59(2):298-308. doi:10.1016/j.molcel.2015.06.011
48. Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev (2016) 30(8):918-30. doi:10.1101/gad.275891.115
49. Ou Y, Wang SJ, Li D, Chu B, Gu W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci U S A (2016) 113(44):E6806-12. doi:10.1073/pnas.1607152113
50. Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep (2018) 22(3):569-75. doi:10.1016/j.celrep.2017.12.077
51. Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep (2017) 20(7):1692-704. doi:10.1016/j.celrep.2017.07.055
52. Feng L, Hollstein M, Xu Y. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle (2006) 5(23):2812-9. doi:10.4161/cc.5.23.3526
53. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, et al. The codon 72 polymorphism of p53 regulates interaction with NF-(kappa)B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol (2011) 31(6):1201-13. doi:10.1128/MCB.01136-10
54. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene (2001) 20(3):320-8. doi:10.1038/sj.onc.1204080
55. Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, et al. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene (2008) 27(19):2788-94. doi:10.1038/sj.onc.1210932
56. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (2016) 63(1):173-84. doi:10.1002/hep.28251
57. Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, et al. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun (2017) 8:14844. doi:10.1038/ncomms14844